Peptron Eyes Differentiation As Exenatide Progresses For Parkinson’s
Executive Summary
With the recent completion of GMP manufacturing facilities and sizable funding, South Korean peptide therapeutics company Peptron is set to begin a Phase II clinical trial of sustained release exenatide for Parkinson’s, which if successful could pave the way to a first-in-class, disease-modifying treatment for the disease.